Efficacy and safety of neoadjuvant immunotherapy in resectable nonsmall cell lung cancer: a meta-analysis

Lung cancer is a major threat to human health. The 2018 global cancer statistics reported that lung cancer has the highest morbidity and mortality of all malignant tumors in the world[1] and nonsmall cell lung cancer (NSCLC) accounts for more than 80% of new diagnoses[2]. Despite the rapid development of anti-tumor therapy in stage I-III NSCLC, 30-60% of the patients progress to metastatic diseases [3]. Moreover, the prognosis of NSCLC is still poor when treated with the combination of neoadjuvant therapy, surgical treatment and adjuvant therapy.
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research